Cargando…

Result on speech perception after conversion from Spectra® to Freedom®

New technology in the Freedom® speech processor for cochlear implants was developed to improve how incoming acoustic sound is processed; this applies not only for new users, but also for previous generations of cochlear implants. AIM: To identify the contribution of this technology – the Nucleus 22®...

Descripción completa

Detalles Bibliográficos
Autores principales: de Matos Magalhães, Ana Tereza, Goffi-Gomez, Maria Valéria Schmidt, Hoshino, Ana Cristina, Tsuji, Robinson Koji, Bento, Ricardo Ferreira, Brito, Rubens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443827/
https://www.ncbi.nlm.nih.gov/pubmed/22499364
http://dx.doi.org/10.1590/S1808-86942012000200003
Descripción
Sumario:New technology in the Freedom® speech processor for cochlear implants was developed to improve how incoming acoustic sound is processed; this applies not only for new users, but also for previous generations of cochlear implants. AIM: To identify the contribution of this technology – the Nucleus 22® – on speech perception tests in silence and in noise, and on audiometric thresholds. METHODS: A cross-sectional cohort study was undertaken. Seventeen patients were selected. The last map based on the Spectra® was revised and optimized before starting the tests. Troubleshooting was used to identify malfunction. To identify the contribution of the Freedom® technology for the Nucleus22®, auditory thresholds and speech perception tests were performed in free field in soundproof booths. Recorded monosyllables and sentences in silence and in noise (SNR = 0dB) were presented at 60 dBSPL. The nonparametric Wilcoxon test for paired data was used to compare groups. RESULTS: Freedom® applied for the Nucleus22® showed a statistically significant difference in all speech perception tests and audiometric thresholds. CONCLUSION: The reedom® technology improved the performance of speech perception and audiometric thresholds of patients with Nucleus 22®.